Cargando…
Reversed Immunoglycomics Identifies α-Galactosyl-Bearing Glycotopes Specific for Leishmania major Infection
[Image: see text] All healthy humans have high levels of natural anti-α-galactosyl (α-Gal) antibodies (elicited by yet uncharacterized glycotopes), which may play important roles in immunoglycomics: (a) potential protection against certain parasitic and viral zoonotic infections; (b) targeting of α-...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American
Chemical Society
2021
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397363/ https://www.ncbi.nlm.nih.gov/pubmed/34467365 http://dx.doi.org/10.1021/jacsau.1c00201 |
_version_ | 1783744598656417792 |
---|---|
author | Montoya, Alba L. Austin, Victoria M. Portillo, Susana Vinales, Irodiel Ashmus, Roger A. Estevao, Igor Jankuru, Sohan R. Alraey, Yasser Al-Salem, Waleed S. Acosta-Serrano, Álvaro Almeida, Igor C. Michael, Katja |
author_facet | Montoya, Alba L. Austin, Victoria M. Portillo, Susana Vinales, Irodiel Ashmus, Roger A. Estevao, Igor Jankuru, Sohan R. Alraey, Yasser Al-Salem, Waleed S. Acosta-Serrano, Álvaro Almeida, Igor C. Michael, Katja |
author_sort | Montoya, Alba L. |
collection | PubMed |
description | [Image: see text] All healthy humans have high levels of natural anti-α-galactosyl (α-Gal) antibodies (elicited by yet uncharacterized glycotopes), which may play important roles in immunoglycomics: (a) potential protection against certain parasitic and viral zoonotic infections; (b) targeting of α-Gal-engineered cancer cells; (c) aiding in tissue repair; and (d) serving as adjuvants in α-Gal-based vaccines. Patients with certain protozoan infections have specific anti-α-Gal antibodies, elicited against parasite-derived α-Gal-bearing glycotopes. These glycotopes, however, remain elusive except for the well-characterized glycotope Galα1,3Galβ1,4GlcNAcα, expressed by Trypanosoma cruzi. The discovery of new parasitic glycotopes is greatly hindered by the enormous structural diversity of cell-surface glycans and the technical challenges of classical immunoglycomics, a top-down approach from cultivated parasites to isolated glycans. Here, we demonstrate that reversed immunoglycomics, a bottom-up approach, can identify parasite species-specific α-Gal-bearing glycotopes by probing synthetic oligosaccharides on neoglycoproteins. This method was tested here seeking to identify as-yet unknown glycotopes specific for Leishmania major, the causative agent of Old-World cutaneous leishmaniasis (OWCL). Neoglycoproteins decorated with synthetic α-Gal-containing oligosaccharides derived from L. major glycoinositolphospholipids served as antigens in a chemiluminescent enzyme-linked immunosorbent assay using sera from OWCL patients and noninfected individuals. Receiver-operating characteristic analysis identified Galpα1,3Galfβ and Galpα1,3Galfβ1,3Manpα glycotopes as diagnostic biomarkers for L. major-caused OWCL, which can distinguish with 100% specificity from heterologous diseases and L. tropica-caused OWCL. These glycotopes could prove useful in the development of rapid α-Gal-based diagnostics and vaccines for OWCL. Furthermore, this method could help unravel cryptic α-Gal-glycotopes of other protozoan parasites and enterobacteria that elicit the natural human anti-α-Gal antibodies. |
format | Online Article Text |
id | pubmed-8397363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American
Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-83973632021-08-30 Reversed Immunoglycomics Identifies α-Galactosyl-Bearing Glycotopes Specific for Leishmania major Infection Montoya, Alba L. Austin, Victoria M. Portillo, Susana Vinales, Irodiel Ashmus, Roger A. Estevao, Igor Jankuru, Sohan R. Alraey, Yasser Al-Salem, Waleed S. Acosta-Serrano, Álvaro Almeida, Igor C. Michael, Katja JACS Au [Image: see text] All healthy humans have high levels of natural anti-α-galactosyl (α-Gal) antibodies (elicited by yet uncharacterized glycotopes), which may play important roles in immunoglycomics: (a) potential protection against certain parasitic and viral zoonotic infections; (b) targeting of α-Gal-engineered cancer cells; (c) aiding in tissue repair; and (d) serving as adjuvants in α-Gal-based vaccines. Patients with certain protozoan infections have specific anti-α-Gal antibodies, elicited against parasite-derived α-Gal-bearing glycotopes. These glycotopes, however, remain elusive except for the well-characterized glycotope Galα1,3Galβ1,4GlcNAcα, expressed by Trypanosoma cruzi. The discovery of new parasitic glycotopes is greatly hindered by the enormous structural diversity of cell-surface glycans and the technical challenges of classical immunoglycomics, a top-down approach from cultivated parasites to isolated glycans. Here, we demonstrate that reversed immunoglycomics, a bottom-up approach, can identify parasite species-specific α-Gal-bearing glycotopes by probing synthetic oligosaccharides on neoglycoproteins. This method was tested here seeking to identify as-yet unknown glycotopes specific for Leishmania major, the causative agent of Old-World cutaneous leishmaniasis (OWCL). Neoglycoproteins decorated with synthetic α-Gal-containing oligosaccharides derived from L. major glycoinositolphospholipids served as antigens in a chemiluminescent enzyme-linked immunosorbent assay using sera from OWCL patients and noninfected individuals. Receiver-operating characteristic analysis identified Galpα1,3Galfβ and Galpα1,3Galfβ1,3Manpα glycotopes as diagnostic biomarkers for L. major-caused OWCL, which can distinguish with 100% specificity from heterologous diseases and L. tropica-caused OWCL. These glycotopes could prove useful in the development of rapid α-Gal-based diagnostics and vaccines for OWCL. Furthermore, this method could help unravel cryptic α-Gal-glycotopes of other protozoan parasites and enterobacteria that elicit the natural human anti-α-Gal antibodies. American Chemical Society 2021-07-12 /pmc/articles/PMC8397363/ /pubmed/34467365 http://dx.doi.org/10.1021/jacsau.1c00201 Text en © 2021 The Authors. Published by American Chemical Society https://creativecommons.org/licenses/by-nc-nd/4.0/Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (https://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Montoya, Alba L. Austin, Victoria M. Portillo, Susana Vinales, Irodiel Ashmus, Roger A. Estevao, Igor Jankuru, Sohan R. Alraey, Yasser Al-Salem, Waleed S. Acosta-Serrano, Álvaro Almeida, Igor C. Michael, Katja Reversed Immunoglycomics Identifies α-Galactosyl-Bearing Glycotopes Specific for Leishmania major Infection |
title | Reversed Immunoglycomics Identifies α-Galactosyl-Bearing
Glycotopes Specific for Leishmania major Infection |
title_full | Reversed Immunoglycomics Identifies α-Galactosyl-Bearing
Glycotopes Specific for Leishmania major Infection |
title_fullStr | Reversed Immunoglycomics Identifies α-Galactosyl-Bearing
Glycotopes Specific for Leishmania major Infection |
title_full_unstemmed | Reversed Immunoglycomics Identifies α-Galactosyl-Bearing
Glycotopes Specific for Leishmania major Infection |
title_short | Reversed Immunoglycomics Identifies α-Galactosyl-Bearing
Glycotopes Specific for Leishmania major Infection |
title_sort | reversed immunoglycomics identifies α-galactosyl-bearing
glycotopes specific for leishmania major infection |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8397363/ https://www.ncbi.nlm.nih.gov/pubmed/34467365 http://dx.doi.org/10.1021/jacsau.1c00201 |
work_keys_str_mv | AT montoyaalbal reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT austinvictoriam reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT portillosusana reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT vinalesirodiel reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT ashmusrogera reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT estevaoigor reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT jankurusohanr reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT alraeyyasser reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT alsalemwaleeds reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT acostaserranoalvaro reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT almeidaigorc reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection AT michaelkatja reversedimmunoglycomicsidentifiesagalactosylbearingglycotopesspecificforleishmaniamajorinfection |